secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-09-23T20:05:41+00:00
Accession:  0001728117-26-000104
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio submits NDA for seralutinib in PAH; FDA acceptance decision expected later 2026
--------------------------------------------------------------------------------

- Submitted NDA to FDA on Sept 23, 2026 for seralutinib treatment of pulmonary arterial hypertension.
- First NDA submission; supported by Phase 3 PROSERA and Phase 2 TORREY studies.
- FDA minutes from June 2026 Pre-NDA meeting called statistical significance a review issue, not filing issue.
- Company expects FDA acceptance decision for filing later this year; approval uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/0001728117-26-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer